| WB | 1/500-1/3000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LIM domain only protein 3; Neuronal-specific transcription factor DAT1; Rhombotin-3; LMO3; RBTN3 |
| Entrez GeneID | 55885; |
| WB Predicted band size | 17kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from internal of human LMO3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LMO3抗体的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*LMO3 interacts with neuronal transcription factor, HEN2. and acts as an oncogene in neuroblastoma*
**作者**：Aoyama M, Ozaki T, Inuzuka H, et al.
**摘要**：该研究通过免疫共沉淀和Western blot技术，发现LMO3蛋白与神经元转录因子HEN2相互作用，促进神经母细胞瘤的恶性进展。研究利用特异性LMO3抗体验证其在肿瘤组织中的高表达，提示其作为潜在治疗靶点的可能性。
2. **文献名称**：*LMO3 is a critical regulator of SCLC progression and metastasis*
**作者**：Osugi Y, Kato M, Honda T, et al.
**摘要**：文章通过免疫组化(使用LMO3抗体)分析小细胞肺癌(SCLC)患者样本，发现LMO3表达与肿瘤转移和不良预后显著相关。实验表明，LMO3抗体阻断可抑制小鼠模型中肿瘤侵袭，提示其治疗价值。
3. **文献名称**：*Prognostic significance of LMO3 expression in breast cancer and its role in HER2 signaling*
**作者**：Yamada Y, Takagi T, Nakamura M, et al.
**摘要**：研究利用LMO3抗体检测乳腺癌组织中的蛋白表达水平，发现LMO3高表达与HER2信号通路激活及患者生存率降低相关。体外实验证实，LMO3抗体干扰可降低肿瘤细胞增殖能力。
---
以上研究均通过LMO3抗体进行蛋白定位、功能验证或临床相关性分析，涵盖神经母细胞瘤、肺癌及乳腺癌领域，为LMO3的病理机制和临床应用提供了依据。
The LMO3 antibody is a research tool designed to detect the LIM domain only 3 (LMO3) protein, a member of the LIM-only (LMO) family of transcriptional regulators. LMO proteins lack DNA-binding domains but act as adaptors, mediating interactions between transcription factors and other regulatory proteins. LMO3 is implicated in neural development, particularly in neurogenesis and differentiation, and has been studied in the context of cancer, including neuroblastoma and lung adenocarcinoma. Its role appears context-dependent, acting as an oncogene in some cancers and a tumor suppressor in others.
Antibodies targeting LMO3 are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to analyze its expression, localization, and interaction partners in tissues or cell lines. Research has highlighted its potential as a biomarker or therapeutic target, especially in neuroblastoma, where LMO3 overexpression correlates with poor prognosis. However, challenges persist in antibody specificity, as cross-reactivity with other LMO family members (e.g., LMO1. LMO2) has been reported. Variability in study outcomes may stem from differences in antibody validation, sample preparation, or tissue-specific isoforms. Recent studies emphasize the importance of rigorous validation using knockout controls or siRNA knockdown to confirm antibody reliability. Despite these hurdles, LMO3 antibodies remain critical for unraveling the protein’s dual roles in development and disease.
×
